Loading
A phase 1/2 trial of BGB-16673 in hodgkin lymphoma and non-hodgkin lymphoma, run by BeiGene, now recruiting.
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader is a phase 1/2 interventional study registered as NCT05294731 by BeiGene, with 146 participants planned, started 2022-05-06 and due to reach its primary completion in 2029-01-31. Interventions recorded: BGB-16673. Conditions listed: B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. No results are recorded here; the registry entry is the source.
Shares BGB-16673, BeOne Medicines (formerly BeiGene), PROTACs & molecular glues (targeted protein degradation), Mantle cell lymphoma.
Shares PROTACs & molecular glues (targeted protein degradation), Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares BeOne Medicines (formerly BeiGene), Mantle cell lymphoma, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares BGB-16673, BeOne Medicines (formerly BeiGene), PROTACs & molecular glues (targeted protein degradation).
Shares BGB-16673, BeOne Medicines (formerly BeiGene), PROTACs & molecular glues (targeted protein degradation).
Shares BeOne Medicines (formerly BeiGene), PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.
Shares BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
Shares PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.